✦ LIBER ✦

All-oral combination of ledipasvir, vedroprevir, tegobuvir, and ribavirin in treatment-naïve patients with genotype 1 HCV infection

✍ Scribed by Wyles, David L.; Rodriguez-Torres, Maribel; Lawitz, Eric; Shiffman, Mitchell L.; Pol, Stanislas; Herring, Robert W.; Massetto, Benedetta; Kanwar, Bittoo; Trenkle, James D.; Pang, Phil S.; Zhu, Yanni; Mo, Hongmei; Brainard, Diana M.; Subramanian, G. Mani; McHutchison, John G.; Habersetzer, François; Sulkowski, Mark S.

Book ID: 121686180
Publisher: John Wiley and Sons
Year: 2014
Tongue: English
Weight: 593 KB
Volume: 60
Category: Article
ISSN: 0270-9139
DOI: 10.1002/hep.27053

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Faldaprevir combined with pegylated inte

Faldaprevir combined with pegylated interferon alfa-2a and ribavirin in treatment-naïve patients with chronic genotype1 HCV: SILEN-C1 trial

✍ Sulkowski, Mark S.; Asselah, Tarik; Lalezari, Jacob; Ferenci, Peter; Fainboim, H 📂 Article 📅 2013 🏛 John Wiley and Sons 🌐 English ⚖ 756 KB

O164 ALL ORAL FIXED-DOSE COMBINATION SOF

O164 ALL ORAL FIXED-DOSE COMBINATION SOFOSBUVIR/LEDIPASVIR WITH OR WITHOUT RIBAVIRIN FOR 12 OR 24 WEEKS IN TREATMENT-NAIVE GENOTYPE 1 HCV-INFECTED PATIENTS: THE PHASE 3 ION-1 STUDY

✍ Mangia, A.; Marcellin, P.; Kwo, P.; Foster, G.R.; Buti, M.; Bräu, N.; Muir, A.; 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 170 KB

Tu2038 All Oral Fixed-dose Combination S

Tu2038 All Oral Fixed-dose Combination Sofosbuvir/Ledipasvir With or Without Ribavirin for 12 or 24 Weeks in Treatment-Naive Genotype 1 HCV-Infected Patients: The Phase 3 ION-1 Study

✍ Jacobson, Ira M.; Marcellin, Patrick; Mangia, Alessandra; Kwo, Paul Y.; Foster, 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 46 KB

12 HIGH SVR12 WITH 16 WEEKS OF TEGOBUVIR

12 HIGH SVR12 WITH 16 WEEKS OF TEGOBUVIR AND GS-9256 WITH PEGINTERFERON-ALFA 2A AND RIBAVIRIN IN TREATMENT-NAIVE GENOTYPE 1 HCV PATIENTS

✍ D.R. Nelson; E. Lawitz; V. Bain; N. Gitlin; T. Hawkins; P. Marotta; K. Workowski 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 127 KB

410 24-WEEK TREATMENT WITH CTS-1027 IN C

410 24-WEEK TREATMENT WITH CTS-1027 IN COMBINATION WITH RIBAVIRIN REDUCES HCV-RNA IN TREATMENT NAIVE GENOTYPE-1 PATIENTS

✍ M. Chojkier; G. Everson; A. Muir; B. Bacon; M. Rodriguez-Torres; M. Bennett; M. 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 81 KB

O56 SOFOSBUVIR/LEDIPASVIR WITH AND WITHO

O56 SOFOSBUVIR/LEDIPASVIR WITH AND WITHOUT RIBAVIRIN FOR 8 WEEKS COMPARED TO SOFOSBUVIR/LEDIPASVIR FOR 12 WEEKS IN TREATMENT-NAÏVE NON-CIRRHOTIC GENOTYPE-1 HCV-INFECTED PATIENTS: THE PHASE 3 ION-3 STUDY

✍ Kowdley, K.V.; Stuart, G.C.; Reddy, R.K.; Rossaro, L.; Bernstein, D.E.; An, D.; 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 172 KB